Cerebral Amyloid Positivity Prediction Models Using Clinical Data in Subjects With Mild Cognitive Impairment and Dementia

Soo-Hyun JOO; Chang-Uk LEE.
Psychiatry Investigation ; : 864-870, 2021.
Artículo en Inglés | WPRIM | ID: wpr-895538

Documentos relacionados

  1. Cerebral Amyloid Positivity Prediction Models Using Clinical Data in Subjects With Mild Cognitive Impairment and Dementia
  2. Cerebral Amyloid Positivity Prediction Models Using Clinical Data in Subjects With Mild Cognitive Impairment and Dementia.
  3. Contributions of sex and genotype to exploratory behavior differences in an aged humanized <i>APOE</i> mouse model of late-onset Alzheimer's disease.
  4. APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors.
  5. Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years.
  6. Plasma nervonic acid levels were negatively associated with attention levels in community-living older adults in New Zealand.
  7. Magnetic susceptibility in the deep gray matter may be modulated by apolipoprotein E4 and age with regional predilections: a quantitative susceptibility mapping study.
  8. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
  9. Neuropsychiatric symptoms and ApoE genotype in older adults without dementia: a cross-sectional study.
  10. Racial differences in the effect of APOE-ε4 genotypes on trail making test B in Alzheimer's disease: A longitudinal study.